SEARCH

SEARCH BY CITATION

References

  • 1
    MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131.
  • 2
    Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev 2002;CD000065.
  • 3
    Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to PCOS. Fertil Steril 2004;81:1925.
  • 4
    Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the PCOS during the reproductive life span. J Clin Endocrinol Metab 2005;90:46508.
  • 5
    Cussons AJ, Stuckey BG, Walsh JP, Burke V, Norman RJ. Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clin Endocrinol (Oxf) 2005;62:28995.
  • 6
    Martin R. A plea for ‘Omics’ research in complex disease such as multiple sclerosis—a change of mind is needed. J Neurol Sci 2004;222:35.
  • 7
    Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int 2008;73:100816.
  • 8
    Zerr I, Bodemer M, Otto M, Poser S, Windl O, Kretzschmar HA, et al. Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid. Lancet 1996;348:8469.
  • 9
    Borro M, Gentile G, Stigliano A, Misiti S, Toscano V, Simmaco M. Proteomic analysis of peripheral T lymphocytes, suitable circulating biosensors of strictly related diseases. Clin Exp Immunol 2007;150:494501.
  • 10
    Choi BC, Kim YS, Kim MS, Chung MK, Choi CH, Baek KH. Identification of overexpressed proteins by proteomic analysis using human follicular fluids derived from polycystic ovary syndrome (PCOS) patients. Fertil Steril 2007;88:S180.
  • 11
    Corton M, Botella-Carretero JI, Lopez JA, Camafeita E, San Millán JL, Escobar-Morreale HF, et al. Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry. Hum Reprod 2008;23:65161.
  • 12
    Ma X, Fan L, Meng Y, Hou Z, Mao YD, Wang W, Ding W, Liu JY. Differential Expression Of Proteins Of Human Ovaries From Normal And Polycystic Ovarian Syndrome By 2-Dimensional Gel Electrophoresis/Mass Spectrometry Analysis. Progress On Post-Genome Technologies. Nanjing: Phoenix Publ & Media Network, 2007.
  • 13
    Ma X, Fan L, Meng Y, Hou Z, Mao YD, Wang W, et al. Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome. Mol Hum Reprod 2007;13:52735.
  • 14
    Matharoo-Ball B, Hughes C, Lancashire L, Tooth D, Ball G, Creaser C, et al. Characterization of biomarkers in PCOS using multiple distinct proteomic platforms. J Proteome Res 2007;6:33218.
  • 15
    Zhao S-Y, Qiao J, Li M-Z, Zhang X-W, Yu J-K, Li R. Preliminary study of protein expression profiling of PCOS on different state. Zhonghua Yi Xue Za Zhi 2008;88:711.
  • 16
    Zhao SY, Qiao J, Li MZ, Zhang X, Yu J, Li R. Discovery of distinct protein profiles for polycystic ovary syndrome with and without insulin resistance by surface-enhanced laser adsorption/ionization time of flight mass spectrometry. Fertil Steril 2007;88:14551.
  • 17
    Zhao SY, Qiao J, Li MZ. Protein expression profilings of polycystic ovary syndrome. Beijing Da Xue Xue Bao 2005;37:3625.
  • 18
    Hughes C, Elgasim M, Layfield R, Atiomo W. Genomic and post-genomic approaches to polycystic ovary syndrome—progress so far: mini review. Hum Reprod 2006;21:276675.
  • 19
    Escobar-Morreale H, Insenser M, Corton M, San Millán JL, Peral B. Proteomics and genomics: a hypothesis-free approach to the study of the role of visceral adiposity in the pathogenesis of the polycystic ovary syndrome. Proteomics Clin Appl 2008;2:44455.
  • 20
    Escobar-Morreale H, Luque-Ramirez M, San Millan J. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005;26:25182.
  • 21
    Escobar-Morreale HF, Millan JLS. Abdominal adiposity and the polycystic ovary syndrome. Trends in Endocrinology and Metabolism 2007;18:26672.
  • 22
    Phillips KP, Foster WG. Key developments in endocrine disrupter research and human health. J Toxicol Environ Health B Crit Rev 2008;11:32244.
  • 23
    Sharma A, Atiomo W. Recent developments in polycystic ovary syndrome. Curr Obstet Gynaecol 2003;13:2816.
  • 24
    Corton M, Villuendas G, Botella JI, San Millán JL, Escobar-Morreale HF, Peral B. Improved resolution of the human adipose tissue proteome at alkaline and wide range pH by the addition of hydroxyethyl disulfide. Proteomics 2004;4:43841.
  • 25
    Wang L, Zhu YF, Guo XJ, Huo R, Ma X, Lin M, et al. A two-dimensional electrophoresis reference map of human ovary. J Mol Med 2005;83:81221.
  • 26
    Wikipedia. Mass spectrometry. 2008. [http://en.wikipedia.org/wiki/Mass_spectrometry]. Accessed 15 September 2008.
  • 27
    Wikipedia. Proteomics. 2008. [http://en.wikipedia.org/wiki/Proteomics]. Accessed 15 September 2008.
  • 28
    Chuthapisith S, Layfield R, Kerr ID, Eremin O. Principles of proteomics and its applications in cancer. Surgeon 2007;5:1422.
  • 29
    Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:117.
  • 30
    Zhang D, Luo WY, Liao H, Wang CF, Sun Y. [The effects of oxidative stress to PCOS]. Sichuan Da Xue Xue Bao Yi Xue Ban 2008;39:4213.
  • 31
    Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003;80:1237.
  • 32
    Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 2001;34:40713.
  • 33
    Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized 48-week, placebo controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004;82:4219.
  • 34
    Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 2006;332:1485.
  • 35
    Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in PCOS: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005;90:601421.
  • 36
    Meek SC, Hodge DD, Musich JR. Autoimmunity in infertile patients with endometriosis. Am J Obstet Gynecol 1988;158:136573.
  • 37
    Yang Y, Chung EK, Zhou B, Lhotta K, Hebert LA, Birmingham DJ, et al. The intricate role of complement component C4 in human systemic lupus erythematosus. Curr Dir Autoimmun 2004;7:98132.
  • 38
    Onat A, Uzunlar B, Hergenc G, Yazici M, Sari I, Uyarel H, et al. Cross-sectional study of complement C3 as a coronary risk factor among men and women. Clin Sci (Lond) 2005;108:12935.
  • 39
    Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo M, Smith C, et al. Mining biomarkers in human sera using proteomic tools. Proteomics 2004;4:24456.
  • 40
    Mischak H, Apweiler R, Banks RE, Conaway M, Coon J, Dominiczak A, et al. Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin Appl 2007;1:14856.
  • 41
    Zintzaras E, Ioannidis JP. Meta-analysis for ranked discovery datasets: theoretical framework and empirical demonstration for microarrays. Comput Biol Chem 2008;32:3947.
  • 42
    Price MJ. The LHC project. Nucl Instrum Meth A 2002;478:4661.
  • 43
    Guterl F, Underhill W, Gardland S. Land of big science. Newsweek 2008;15:423.